Benzimidazole-derived VEGFR-2 inhibitors: Docking, ADMET, anticancer evaluations, design and synthesis

Key Points

• Inhibition of VEGFR-2 exhibited significant anticancer effects in multiple cell lines, with a notable potency observed.
• The docking studies indicated favorable binding affinities of the benzimidazole derivatives to the VEGFR-2 receptor.
• Assessment of ADMET properties demonstrated promising pharmacokinetic profiles for the synthesized compounds.
• These findings highlight the potential of benzimidazole derivatives as effective cancer therapeutics targeting VEGFR-2.